Last Price
85.47
Today's Change
+8.72 (11.36%)
Day's Change
76.76 - 88.00
Trading Volume
2,500,499
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Sharon Mates Ph.D. Dr. Sharon Mates Ph.D.
Full Time Employees: 610 610
IPO Date: 2014-01-07 2014-01-07
CIK: 0001567514 0001567514
ISIN: US46116X1019 US46116X1019
CUSIP: 46116X101 46116X101
Beta: 1.00 1.00
Last Dividend: 0.00 0.00
Dcf Diff: 69.99 69.99
Dcf: -1.61 -1.61
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.